US and EU regulators target structural foundations of life sciences industry

For more than a decade the life sciences industry has built itself around vertical integration. Insurers bought pharmacy benefit managers. Pharmacy benefit managers bought specialty pharmacies. Manufacturers relied on long regulatory exclusivity periods to recoup development costs. In the space of a few months, both Washington and Brussels have signalled that this architecture is now up for negotiation.

In the United States, the Break Up Big Medicine Act would compel certain insurers and pharmacy benefit managers to spin off their pharmacy operations. In the European Union, the Commission's April 2023 pharmaceutical package proposes cutting the baseline regulatory data protection period from eight years to six, with the possibility of regaining lost time only if companies meet new access and supply conditions. The two moves differ in mechanism but share a premise: regulators are no longer satisfied with policing behaviour within existing structures. They are questioning the structures themselves.

The American model under scrutiny

The Break Up Big Medicine Act represents a departure from the traditional antitrust and reimbursement battles that have defined US healthcare enforcement. Rather than alleging specific anti-competitive conduct, the legislation targets the ownership model itself. If enacted, companies that combine insurance, pharmacy benefit management and pharmacy dispensing would face mandatory divestiture within a compressed timeframe.

The practical consequences extend well beyond corporate restructuring. Boards and general counsel must now contemplate how to value pharmacy assets under forced-sale conditions, whether existing debt covenants restrict such structural changes, whether provider and pharmacy contracts can be reassigned, and how state regulators would treat the newly separated entities. Publicly traded groups may need to revise risk disclosures in securities filings, while investors reassess valuation models built on integrated revenue streams.

"Congress is no longer asking whether integrated companies are complying with existing law. The question now seems to focus on whether certain business models should exist at all," said Ron Lanton III, senior partner at Lanton, Lanton & Sosa Law, in his analysis of the legislative shift.

Brussels rewrites the exclusivity calculus

The European Commission's proposal, formally the Proposal for a Directive on the Union Code Relating to Medicinal Products for Human Use, takes aim at the "8+2+1" framework that has governed regulatory data protection since 2001. Under the current system, originator companies enjoy eight years during which generic rivals cannot reference their clinical trial data, followed by two years of market protection and a possible one-year extension for new therapeutic indications.

The Commission would reduce the base period to six years. Additional protection, up to the current eight-year equivalent, would become conditional. Companies could regain time by launching in all 27 member states, addressing unmet medical needs, or meeting supply continuity obligations. The effect is to transform exclusivity from an automatic right into a performance-based incentive.

This distinction matters. Regulatory data protection operates independently of patent protection. A molecule may still enjoy 20 years of patent life from filing, but the ability of generics and biosimilars to rely on the originator's trial data for marketing authorisation determines when competition can practically enter. Shortening that window compresses the effective commercial life of a product, particularly for smaller biotechnology firms that lack the infrastructure to launch simultaneously across two dozen national markets with divergent pricing, reimbursement and distribution systems.

Smaller biotechs face disproportionate burden

The requirement to launch across all 27 member states within a short timeframe to qualify for restored protection creates a structural advantage for large multinational companies. A mid-sized biotech with a novel oncology product may secure approval in Germany, France and Italy within 18 months but face years of negotiation in smaller markets where health technology assessment bodies operate on different timetables and pricing frameworks vary widely.

The Commission's impact assessment acknowledges these disparities but argues that the current system rewards late or selective launches. The policy goal is to ensure patients across the Union benefit from innovation simultaneously. The tension between that objective and the operational reality of 27 distinct reimbursement negotiations remains unresolved in the legislative text.

Capital markets already pricing uncertainty

Even before legislation is finalised, the signalling effect is measurable. Analysts covering European pharmaceutical groups have begun modelling scenarios with six-year data exclusivity as a base case. In the United States, healthcare conglomerates with significant pharmacy benefit manager and retail pharmacy exposure have seen increased volatility around committee hearings on the Break Up Big Medicine Act.

Debt markets are watching closely. Covenants in existing bond indentures and loan agreements often restrict asset sales, change of control or fundamental restructuring without lender consent. A mandatory divestiture could trigger technical defaults or require costly waivers. Equity investors are reassessing the premium historically assigned to integrated models, which promised data advantages, distribution control and negotiating leverage across the supply chain.

A philosophical convergence across the Atlantic

The US and EU approaches reflect different legal traditions. Washington reaches for structural separation through antitrust-adjacent legislation. Brussels uses the regulatory code to align commercial incentives with public health objectives. Yet both represent a move away from the post-1990s consensus that vertical integration and strong exclusivity were legitimate efficiency drivers.

That consensus held that integrated companies could reduce transaction costs, coordinate care and amortise R&D across larger patient populations. The new view, visible in both capitals, is that integration creates conflicts of interest, insurers steering patients to owned pharmacies, PBMs favouring products with higher rebates, and that long exclusivity periods delay affordable access without demonstrably increasing innovation output.

Legal departments rewriting playbooks

For in-house counsel and external advisers, the implications cascade across practice areas. M&A due diligence now requires modelling forced divestiture scenarios. Intellectual property strategy must account for a weaker regulatory exclusivity baseline in Europe. Commercial teams need launch plans that satisfy the Commission's access conditions without triggering parallel trade or reference pricing penalties. Compliance functions must prepare for a regime where business model design is itself a regulatory risk.

The speed of the policy cycle is notable. The Commission's proposal arrived in April 2023. The European Parliament and Council are negotiating amendments with a view to adoption before the 2024 elections. In Washington, the Break Up Big Medicine Act has moved from concept to committee markup in a single congressional session. Companies that treated structural reform as a theoretical tail risk now face it as a near-term planning assumption.